Randomized studies involving consolidation therapy post-ASCT
| Reference . | Consolidation regimen . | Response rates (pre- and post-) % . | PFS . | OS . |
|---|---|---|---|---|
| 23, 56 | VTD vs TD | nCR/CR rates | 3-y PFS: 60% (VTD) vs 48% (TD) (P = .042) | 3-y OS: 90% (VTD) vs 88% (TD) (P = .39) |
| VTD: 63→73 | ||||
| TD: 55→61 | ||||
| 24 | V vs none | nCR/CR rates | Median PFS: 27 (V) vs 20 (none) mo (P = .05) | Median OS not reached for either arm (P = .4) |
| V: 20→45 | ||||
| None: 21→35 | ||||
| 25 | V vs none | ≥VGPR rates | Median PFS: 33.6 (V) vs 27.8 (none) mo (P = .0058) | Median OS not reached for either arm (P = .75) |
| V: 55→62 | ||||
| None: 59→48 |
| Reference . | Consolidation regimen . | Response rates (pre- and post-) % . | PFS . | OS . |
|---|---|---|---|---|
| 23, 56 | VTD vs TD | nCR/CR rates | 3-y PFS: 60% (VTD) vs 48% (TD) (P = .042) | 3-y OS: 90% (VTD) vs 88% (TD) (P = .39) |
| VTD: 63→73 | ||||
| TD: 55→61 | ||||
| 24 | V vs none | nCR/CR rates | Median PFS: 27 (V) vs 20 (none) mo (P = .05) | Median OS not reached for either arm (P = .4) |
| V: 20→45 | ||||
| None: 21→35 | ||||
| 25 | V vs none | ≥VGPR rates | Median PFS: 33.6 (V) vs 27.8 (none) mo (P = .0058) | Median OS not reached for either arm (P = .75) |
| V: 55→62 | ||||
| None: 59→48 |
V, bortezomib; VGPR, very-good-partial response.